446 related articles for article (PubMed ID: 8862709)
21. Taxoids: a new class of cytotoxic agents.
Marty M; Extra JM; Giacchetti S; Cuvier C; Espie M
Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S25-8. PubMed ID: 7909941
[TBL] [Abstract][Full Text] [Related]
22. Docetaxel (Taxotere): preclinical and general clinical information.
Earhart RH
Semin Oncol; 1999 Oct; 26(5 Suppl 17):8-13. PubMed ID: 10604262
[TBL] [Abstract][Full Text] [Related]
23. The taxoids. Comparative clinical pharmacology and therapeutic potential.
Eisenhauer EA; Vermorken JB
Drugs; 1998 Jan; 55(1):5-30. PubMed ID: 9463787
[TBL] [Abstract][Full Text] [Related]
24. Paclitaxel (Taxol) and docetaxel (Taxotere): active chemotherapeutic agents in lung cancer.
Francis PA; Kris MG; Rigas JR; Grant SC; Miller VA
Lung Cancer; 1995 Apr; 12 Suppl 1():S163-72. PubMed ID: 7551925
[TBL] [Abstract][Full Text] [Related]
25. Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination.
Bissery MC; Vrignaud P; Lavelle F
Semin Oncol; 1995 Dec; 22(6 Suppl 13):3-16. PubMed ID: 8604451
[TBL] [Abstract][Full Text] [Related]
26. Docetaxel in anthracycline-resistant metastatic breast cancer.
Hui YF; Ignoffo RJ
Cancer Pract; 1997; 5(2):124-7. PubMed ID: 9110651
[TBL] [Abstract][Full Text] [Related]
27. 'Rings' of F-actin form around the nucleus in cultured human MCF7 adenocarcinoma cells upon exposure to both taxol and taxotere.
Rosenblum MD; Shivers RR
Comp Biochem Physiol C Toxicol Pharmacol; 2000 Jan; 125(1):121-31. PubMed ID: 11790336
[TBL] [Abstract][Full Text] [Related]
28. Docetaxel.
Cortes JE; Pazdur R
J Clin Oncol; 1995 Oct; 13(10):2643-55. PubMed ID: 7595719
[TBL] [Abstract][Full Text] [Related]
29. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
Petrylak DP
Semin Oncol; 2000 Apr; 27(2 Suppl 3):24-9. PubMed ID: 10810935
[TBL] [Abstract][Full Text] [Related]
30. Preclinical pharmacology of docetaxel.
Bissery MC
Eur J Cancer; 1995; 31A Suppl 4():S1-6. PubMed ID: 7577097
[TBL] [Abstract][Full Text] [Related]
31. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience.
Bissery MC; Nohynek G; Sanderink GJ; Lavelle F
Anticancer Drugs; 1995 Jun; 6(3):339-55, 363-8. PubMed ID: 7670132
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo.
Tanaka M; Obata T; Sasaki T
Eur J Cancer; 1996 Feb; 32A(2):226-30. PubMed ID: 8664032
[TBL] [Abstract][Full Text] [Related]
33. Docetaxel.
Leahy M; Howell A
Br J Hosp Med; 1997 Feb 19-Mar 4; 57(4):141-4. PubMed ID: 9166374
[TBL] [Abstract][Full Text] [Related]
34. Taxoids: effective agents in anthracycline-resistant breast cancer.
Ravdin PM
Semin Oncol; 1995 Dec; 22(6 Suppl 13):29-34. PubMed ID: 8604450
[TBL] [Abstract][Full Text] [Related]
35. Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer.
Ravdin PM
Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-18-S10-21. PubMed ID: 9275002
[TBL] [Abstract][Full Text] [Related]
36. [Taxoids: structural and experimental properties].
Lavelle F; Combeau C; Commerçon A
Bull Cancer; 1995 Apr; 82(4):249-64. PubMed ID: 10846536
[TBL] [Abstract][Full Text] [Related]
37. Role of taxoids in head and neck cancer.
Schrijvers D; Vermorken JB
Oncologist; 2000; 5(3):199-208. PubMed ID: 10884498
[TBL] [Abstract][Full Text] [Related]
38. Weekly administration of docetaxel (Taxotere): summary of clinical data.
Hainsworth JD; Burris HA; Greco FA
Semin Oncol; 1999 Jun; 26(3 Suppl 10):19-24. PubMed ID: 10437747
[TBL] [Abstract][Full Text] [Related]
39. Paclitaxel and docetaxel in breast and ovarian cancer.
Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
[TBL] [Abstract][Full Text] [Related]
40. Enhanced transgene expression in androgen independent prostate cancer gene therapy by taxane chemotherapeutic agents.
Li Y; Okegawa T; Lombardi DP; Frenkel EP; Hsieh JT
J Urol; 2002 Jan; 167(1):339-46. PubMed ID: 11743353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
